Winston's crusade
OPINION: A short-term sugar hit. That's what NZ First leader Winston Peters is calling the proposed sale of Fonterra's consumer and associated businesses.
Fonterra is selling its 50% share of DFE Pharma for $633million.
The deal with private equity firm, CVC Strategic Opportunities II is made up of a cash payment of $537 million, payable on completion of the sale, plus an interest-accruing vendor loan of $96 million, for a term of up to 15 years. Built into the deal is a potential additional payment of up to $44 million based on DFE’s performance over two years.
The sale is subject to receipt of regulatory approvals from competition authorities.
Fonterra says the cash from this sale, along with proceeds from our other asset sales across the year – which includes the significant contribution from Tip Top – will give it over $1 billion available for debt reduction.
Fonterra chief executive Miles Hurrell says the co-op set itself a tough initial target for debt reduction.
“We are pleased with the progress we are making. It’s an important milestone in our co-op’s plan to lift our business performance.
“A year ago, we started a full portfolio review to re-evaluate every investment, major asset and partnership, to make sure they were still right for the co-op.”
In March, Fonterra announced it was reviewing its share of DFE Pharma, a 50% joint venture with Royal Friesland Campina. DFE Pharma was identified for sale due to the substantial capital required for its future growth.
“We are now at the end of that process and have sold our share of DFE Pharma to CVC Strategic Opportunities II, a fund managed by CVC Capital Partners, a leading private equity and investment advisory firm, managing approximately US$83 billion of assets in 73 companies worldwide,” Hurrell says.
Hurrell says that Fonterra was pleased to have secured a good sale price and will stay committed to the ongoing success of the DFE Pharma business through a long-term supply agreement and the interest-accruing vendor loan.
“A big part of the success of DFE Pharma has been the high-quality lactose produced by the team at Fonterra’s Kapuni site in Taranaki and it is a good outcome to be able to continue to supply this.
“This milestone, along with the significant inroads made in our capital and operational expenditure during FY19, makes for a good initial chapter in our business turn-around. It puts us on the right footing to deliver our new strategy and a sustainable lift in our performance.” says Hurrell
A major feature of the Ashburton A&P Show, to be held on October 31 and November 1, will be the annual trans-Tasman Sheep Dog Trial test match, with the best heading dogs from both sides of the Tasman going head-to-head in two teams of four.
Fewer bobby calves are heading to the works this season, as more dairy farmers recognise the value of rearing calves for beef.
The key to a dairy system that generates high profit with a low emissions intensity is using low footprint feed, says Fonterra program manager on-farm excellence, Louise Cook.
Rural retailer Farmlands has reported a return to profitability, something the co-operative says shows clear progress in the second year of its five-year strategy.
According to a new report, the Safer Rides initiative, which offered farmers heavily discounted crush protection devices (CPDs) for quad bikes, has made a significant impact in raising awareness and action around farm vehicle safety.
OPINION: In the past weeks, much has been said and written about one of New Zealand's greatest prime ministers, James Brendan Bolger, who died just a few months after his 90th birthday.